Unlocking Obesity Solutions Through Precision Target Discovery

Our obesity-related therapeutic target identification service at Protheragen leverages genetic, transcriptomic, and proteomic data to identify key molecular targets involved in obesity by integrating genome-wide association studies (GWAS), expression quantitative trait loci (eQTL), protein-protein interaction (PPI) networks, and drug-gene interaction databases, enabling the discovery of novel genes, pathways, and proteins that are modulated for therapeutic purposes, enhancing the efficacy of obesity treatments through drug development and repurposing.

At Protheragen, our obesity-related candidate gene identification service identifies novel genetic and molecular targets for obesity treatment by uncovering key genes and pathways involved in obesity development. In parallel, our obesity-related drug-gene interaction analysis service aids pharmaceutical companies in developing new drugs or repurposing existing ones by analyzing the interactions between these identified genes and potential therapeutic compounds.

Our service process begins with obesity-related candidate gene identification, where we analyze genetic data using advanced bioinformatics tools to identify key genes and pathways linked to obesity. Once the candidate genes are identified, the obesity-related drug-gene interaction analysis evaluates potential drug interactions by leveraging molecular docking simulations and drug-gene interaction databases. This dual approach ensures a thorough exploration of genetic targets and their therapeutic potential, providing pharmaceutical companies with actionable insights for drug development or repurposing and supporting the creation of personalized obesity treatments.

Data Acquisition and Integration

The process begins by acquiring genetic, transcriptomic, and proteomic data related to obesity from public databases (e.g., GWAS and eQTL studies).

Gene and Target Prioritization

GWAS and eQTL analysis prioritize obesity-associated genes, followed by PPI network construction to identify hub genes central to obesity's molecular mechanisms.

Drug-gene Interaction Analysis

Drug-gene interaction databases are queried to identify approved drugs that target obesity-related genes, facilitating drug repurposing efforts.

Validation and Reporting

Molecular docking simulations and pathway enrichment analyses validate the therapeutic potential of identified targets. A detailed report is generated, summarizing the findings and providing recommendations for potential drug targets and interventions.

Anti-Obesity Therapy Development

In addition to this, we provide a one-stop service for the development of anti-obesity therapies and conduct detailed preclinical studies.

Applications

• Identifying novel molecular targets for obesity facilitates the development of new drugs designed to modulate these targets, offering more effective treatments for obesity.
• By analyzing drug-gene interactions, this service helps in repurposing existing drugs that interact with obesity-related genes, accelerating the therapeutic discovery process.
• The service provides insights into individual genetic profiles, enabling the design of personalized therapies that target specific genes contributing to a patient's obesity.
• Pharmaceutical companies and researchers can utilize this service for preclinical studies to validate genetic targets and test potential therapeutic compounds.

Advantages

• The service integrates genetic, transcriptomic, and proteomic data, offering a complete view of obesity-related molecular mechanisms.
• By identifying and prioritizing key genes, pathways, and drug-gene interactions, this service enhances the precision and efficacy of drug development efforts.
• Leveraging in silico bioinformatics tools reduces the time and cost associated with traditional drug discovery methods.
• The integration of multiple data sources ensures the identification of the most relevant and actionable therapeutic targets.

Publication

Frequently Asked Questions

1. What is the purpose of the obesity-related therapeutic target identification service?

   The purpose of the obesity-related therapeutic target identification service is to pinpoint critical genetic and molecular factors involved in obesity, supporting the creation of innovative drugs and tailored treatment strategies.

2. What is the role of the drug-gene interaction analysis service?

   This service evaluates the interactions between identified obesity-related genes and existing drugs, helping to repurpose approved drugs or guide the development of new therapies.

3. How can this service support personalized medicine?

   By identifying the specific genetic factors contributing to a patient's obesity, the service enables the design of tailored treatment plans that target these genes for more effective outcomes.

At Protheragen, our service provides a comprehensive solution for discovering and validating key genetic and molecular targets involved in obesity. By integrating advanced bioinformatics tools, including molecular docking, GWAS, and drug-gene interaction databases, Protheragen identifies novel therapeutic targets and evaluates existing drug interactions to facilitate new drug development and repurposing. Please feel free to contact us for more information about our services and anti-obesity solutions.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Bioinformatics-based New Obesity Gene Screening Service
• Blood Test-based Obesity Prediction Service
• Genetic and Epigenetic Sequencing-Based Obesity Risk Analysis Service
• Machine Learning and Predictive Modeling
• Physio-psycho-social Model-based Obesity Prediction Service